Oncovascular Reconstruction, Vascular Tumors, and Complex Regional/Functional Vascular Problems

69.1Classification and presentation

Vascular tumors and malformations are distinct clinical entities governed by their biological behavior. Management depends on accurate classification rather than the mere presence of a vascular mass. The ISSVA classification separates vascular tumors from vascular malformations and categorizes tumors as benign (infantile hemangioma), locally aggressive or borderline (kaposiform hemangioendothelioma), and malignant (angiosarcoma, epithelioid hemangioendothelioma) ISSVA 2018. Oncovascular problems involve the encasement or invasion of major blood vessels by nonvascular tumors, such as retroperitoneal sarcoma or gastrointestinal stromal tumors.

Presenting features and clinical threats driving intervention include:

• Threat to airway, vision, or limb function.
• Loss of skin integrity, ulceration, or bleeding.
• Vascular access failure.
• Compression of adjacent structures or localized ischemia.
• Consumptive coagulopathy (Kasabach-Merritt phenomenon) in complicated tumors.
• Venous hypertension or lymphatic dysfunction.

69.2Treatment thresholds and management pathways

Intervention answers a specific threat while the underlying disease is managed systemically or oncologically. Vascular resection and reconstruction are indicated when they enable a planned margin-directed cancer operation, not as independent technical endpoints. Catheter-based intervention is a distinct treatment arm alongside systemic therapy, surgery, and oncologic resection: image-guided sclerotherapy and catheter embolization control vascular malformations and complicated vascular anomalies such as kaposiform hemangioendothelioma with Kasabach-Merritt phenomenon, transarterial embolization controls bleeding or ulcerating vascular tumors, and preoperative embolization of hypervascular tumors before oncovascular resection reduces intraoperative blood loss.

Treatment decision logic follows an ordered approach:

1. Lesion classification is established using ISSVA terminology or oncologic tissue diagnosis.
2. The active medical or multidisciplinary sarcoma team leading the systemic plan is identified.
3. First-line medical therapy is used for benign and locally aggressive tumors prior to surgical consideration.
4. The specific surgical endpoint is defined: symptom relief, access preservation, or enabling an en-bloc margin-directed resection.
5. Absolute contraindications to reconstruction are established, including loss of a realistic margin, unexpected metastatic disease changing intent, or excessive anticipated morbidity.

69.3Medical and systemic therapy

Systemic management precedes or dictates the boundaries of surgical intervention. For infantile hemangioma, oral propranolol is the primary treatment for proliferating lesions requiring systemic therapy HERO (2015). Medical-first management centers on early specialist referral and propranolol administration to prevent irreversible functional impairment or scarring AAP 2019.

Kaposiform hemangioendothelioma associated with Kasabach-Merritt phenomenon requires treatment of the systemic consumptive coagulopathy rather than isolated local excision KHE Consensus · 2013. Sirolimus, an mTOR inhibitor, is a systemic option for complicated vascular anomalies refractory to prior therapy, achieving partial response in approximately 83 percent at end of course 6 and 85 percent at end of course 12 Adams 2016.

Most gastrointestinal stromal tumors carry an activating KIT or PDGFRA proto-oncogene mutation, providing a target for the tyrosine kinase inhibitor imatinib mesylate DeMatteo 2009. Three years of adjuvant imatinib significantly improves recurrence-free and overall survival compared with one year of therapy in high-risk resected GIST (SSGXVIII/AIO) SSGXVIII (2020) · SSGXVIII (2012). A minimum of 3 years of adjuvant imatinib is indicated after complete resection of high-risk KIT-positive tumors ESMO 2022. Vascular intervention must preserve a path to complete this postoperative systemic therapy.

69.4Oncovascular reconstruction strategy

In retroperitoneal sarcoma, en-bloc multivisceral resection is the standard approach, incorporating the resection of involved major vascular structures when necessary to achieve oncologic clearance TARPSWG 2015. The procedure is planned as a cancer operation rather than a local vascular exposure problem.

Vascular replacement, repair, or ligation is tailored to the individual anatomy, available collateral flow, venous territory, and contamination risk. Major vascular resection and reconstruction are used in selected retroperitoneal sarcoma cases, contingent upon multidisciplinary consensus regarding the intended oncologic outcome RPS Reconstruction Review 2023 · Major Vascular Resection 2021. Rescue strategies, including proximal and distal control, blood-loss management, and alternate conduits, are established prior to vessel division.

69.5Postoperative surveillance

Postoperative follow-up requires integrated assessment of vascular function and oncologic disease control. Vascular surveillance evaluates graft patency, limb or organ perfusion, access function, and the absence of venous hypertension or wound complications. Oncologic surveillance confirms progression into the appropriate systemic or adjuvant pathway, such as the mandated 3-year imatinib regimen for gastrointestinal stromal tumors ESMO 2022 · SSGXVIII (2012). Complications are interpreted in the context of the tumor biology and subsequent treatment schedule, rather than as isolated technical events.

69.6Areas of controversy

The exact conduit hierarchy, optimal anticoagulation duration, and specific diameter or flow thresholds for venous reconstruction in retroperitoneal sarcoma are not uniformly established and remain center-driven RPS Reconstruction Review 2023 · Major Vascular Resection 2021. The trade-offs between extensive limb-salvage reconstruction and primary amputation in locally advanced extremity sarcomas lack definitive consensus guidelines. Furthermore, graft surveillance intervals specific to oncovascular reconstruction remain poorly defined and are currently extrapolated from peripheral bypass and trauma standards.